focus -WSS

focus

author：leisure time 2025-09-07 21:55:35 - browse：61751

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Ukraine and a new approach to mental health in war

focus

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

It's been 20 years since Dolly the sheep. Where's my clone?

Ukraine and a new approach to mental health in war

New Ultima Genomics DNA sequencer can read genome for $100

Ukraine and a new approach to mental health in war

CDC's new outbreak response network to include Northeastern

Wikipedia

focus

explore

Walensky prepares to leave CDC — and Congress — behind

Covid misinformation case heads to Supreme Court

The high cost of giving birth even with insurance

Cognito secures funding to test medical device for Alzheimer's

Continuity nursing helped my family in our darkest PICU moments

Drug for rare kidney disease narrowly misses mark in clinical trial

How one medical school became remarkably diverse

Emergency workers more likely to restrain Black patients: study

Continuity nursing helped my family in our darkest PICU moments

Time to name cancers by genetics, not organ of origin, expert says

focus

Time to name cancers by genetics, not organ of origin, expert says

Ukraine and a new approach to mental health in war

Senators: Long

Drug for rare kidney disease narrowly misses mark in clinical trial

Senators: Long

General Catalyst, Summa Health deal will turn on physician buy

explore

knowledge

focus

Wikipedia